Committee Recommends Continuation Of Phase III Study Of StemEx For Leukemia And Lymphoma

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

The Gamida Cell-Teva Joint Venture (JV) announced that the Data Monitoring Committee (DMC) has independently reviewed preliminary data from the pivotal registration, Phase III clinical trial of StemEx (called ExCell) and has recommended that the JV continue to enroll patients in this study.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.